Amantadine controlled-release - Adamas

Drug Profile

Amantadine controlled-release - Adamas

Alternative Names: ADS-5101; ADS-5102; amantadine ER; amantadine HCl; amantadine HCl extended release; Nurelin

Latest Information Update: 16 Jun 2017

Price : $50

At a glance

  • Originator Adamas Pharmaceuticals
  • Class Adamantanes; Antiparkinsonians; Antivirals; Organic bridged compounds; Small molecules
  • Mechanism of Action Dopamine receptor agonists; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Drug-induced dyskinesia
  • New Molecular Entity No
  • Available For Licensing Yes - Dyskinesias

Highest Development Phases

  • Preregistration Drug-induced dyskinesia
  • Phase II Movement disorders
  • Discontinued Brain injuries

Most Recent Events

  • 08 Jun 2017 Updated efficacy and adverse events data from the phase III EASE LID 2 trial in Drug induced dyskinesia presented at the 21st International Congress of Parkinson’s Disease and Movement Disorders
  • 24 Apr 2017 Safety and efficacy data from a pooled analysis from the phase III EASE LID and EASE LID 3 trials in Drug-induced dyskinesia reported at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
  • 28 Feb 2017 Interim adverse events and efficacy data from the phase III EASE LID 2 trial in Drug induced dyskinesia released by Adamas Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top